多发性骨髓瘤的B细胞成熟抗原靶向嵌合抗原受体T细胞治疗与复发后处理的研究进展

doi:10.3969/j.issn.1006-5725.2025.07.001

Abstract

Abstract:

Multiple myeloma （MM） is a prevalent hematological malignancy. Despite the availability of various therapeutic agents， disease relapse remains inevitable. In recent years， B cell maturation antigen （BCMA）?targeted chimeric antigen receptor T （CAR?T） cell therapy has demonstrated remarkable success in treating relapsed/refractory （R/R） MM， offering new hope for RRMM patients. Currently， four types of BCMA?CAR?T products are available on the global market， and their application in RRMM is becoming increasingly widespread. However， RRMM patients who receive BCMA?CAR?T treatment still exhibit a high relapse rate. Research on maintenance therapy following BCMA?CAR?T treatment is currently limited， and multiple strategies exist for managing post?relapse RRMM after BCMA?CAR?T therapy.

Key words: multiple myeloma, BCMA-CAR-T, relapse

CLC Number:

R552

Sijia YAN,Yi XIAO. Advances in BCMA⁃CAR⁃T therapy of multiple myeloma and management after relapse[J]. The Journal of Practical Medicine, 2025, 41(7): 929-935.

Figures/Tables 1

References 44

1	FIRTH J. Haematology： multiple myeloma［J］. Clin Med （Lond），2019，19（1）：58-60. doi:10.7861/clinmedicine.19-1-58 doi: 10.7861/clinmedicine.19-1-58
2	KAZANDJIAN D. Multiple myeloma epidemiology and survival： A unique malignancy［J］. Semin Oncol， 2016，43（6）：676-681. doi:10.1053/j.seminoncol.2016.11.004 doi: 10.1053/j.seminoncol.2016.11.004
3	LEE L， BOUNDS D， HERLEDAN G， et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma［J］. Br J Haematol， 2016，174（6）：911-922. doi:10.1111/bjh.14145 doi: 10.1111/bjh.14145
4	POORNIMA S， BINDU K， BINDU G， et al. FDA Approval Summary： Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma［J］. Clin Cancer Res， 2022，28（9）：1759-1764. doi:10.1158/1078-0432.ccr-21-3803 doi: 10.1158/1078-0432.ccr-21-3803
5	KAVITA N， MEGHA K， BINDU G， et al. FDA Approval Summary： Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma［J］. Clin Cancer Res， 2024，30（14）：2865-2871. doi:10.1158/1078-0432.ccr-24-0378 doi: 10.1158/1078-0432.ccr-24-0378
6	KEAM S J. Equecabtagene Autoleucel： First Approval［J］. Mol Diagn Ther， 2023，27（6）：781-787. doi:10.1007/s40291-023-00673-y doi: 10.1007/s40291-023-00673-y
7	LIN Y， RAJE N S， BERDEJA J G， et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma： Post hoc 18-month follow-up of a phase 1 trial［J］. Nat Med， 2023，29（9）：2286-2294. doi:10.1038/s41591-023-02496-0 doi: 10.1038/s41591-023-02496-0
8	MUNSHI N C， ANDERSON L D， SHAH N， et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma［J］. N Engl J Med， 2021，384（8）：705-716. doi:10.1056/nejmoa2024850 doi: 10.1056/nejmoa2024850
9	RODRIGUEZ-OTERO P， AILAWADHI S， ARNULF B， et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma［J］. N Engl J Med， 2023，388（11）：1002-1014. doi:10.1056/nejmoa2213614 doi: 10.1056/nejmoa2213614
10	MARTIN T， USMANI S Z， BERDEJA J G， et al. Ciltacabtagene Autoleucel， an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy， for Relapsed/Refractory Multiple Myeloma： CARTITUDE-1 2-Year Follow-Up［J］. J Clin Oncol， 2023，41（6）：1265-1274. doi:10.1200/jco.22.00842 doi: 10.1200/jco.22.00842
11	ZHAO W H， WANG B Y， CHEN L J， et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma： A phase 1， single-arm， open-label， multicenter study in China （LEGEND-2）［J］. J Hematol Oncol， 2022，15（1）：86. doi:10.1186/s13045-022-01301-8 doi: 10.1186/s13045-022-01301-8
12	MI J Q， ZHAO W， JING H， et al. Phase II， Open-Label Study of Ciltacabtagene Autoleucel， an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy， in Chinese Patients With Relapsed/Refractory Multiple Myeloma （CARTIFAN-1）［J］. J Clin Oncol，2023，41（6）：1275-1284. doi:10.1200/jco.22.00690 doi: 10.1200/jco.22.00690
13	VAN DE DONK N W J C， MOUNZER A， ADAM D C， et al. Ciltacabtagene Autoleucel （Cilta-cel）， a BCMA-Directed CAR-T Cell Therapy， in Patients with Multiple Myeloma （MM） and Early Relapse after Initial Therapy： CARTITUDE-2 Cohort B 18-Month Follow-up［J］. Blood， 2022，140 （）： 7536-7537. doi:10.1182/blood-2022-159169 doi: 10.1182/blood-2022-159169
14	COHEN A， EINSELE H， DELFORGE M， et al. OAB-045： Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel （cilta-cel） in lenalidomide-refractory multiple myeloma after 1–3 prior lines of therapy： CARTITUDE-2 Cohort A［J］. Clin Lymphoma Myeloma， 2022， 22： S27-S28. doi:10.1016/s2152-2650(22)00318-4 doi: 10.1016/s2152-2650(22)00318-4
15	European Myeloma Network. A Phase 3 Randomized Study Comparing Daratumumab， Bortezomib， Lenalidomide and Dexamethasone （DVRd） Followed by Ciltacabtagene Autoleucel Versus Daratumumab， Bortezomib， Lenalidomide and Dexamethasone （DVRd） Followed by Autologous Stem Cell Transplant （ASCT） in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible： NCT05257083［R］. clinicaltrials.gov， 2023.
16	SAN-MIGUEL J， DHAKAL B， YONG K， et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma［J］. N Engl J Med， 2023，389（4）：335-347.
17	LI C， WANG D， FANG B， et al. Updated long-term follow-up results of a phase 1b/2 study （FUMANBA-1） in patients with relapsed/refractory multiple myeloma （RRMM） treated with equecabtagene autoleucel［J］. Clin Lymphoma Myeloma， 2023， 23： S196-S197. doi:10.1016/s2152-2650(23)01908-0 doi: 10.1016/s2152-2650(23)01908-0
18	LI C， WANG D， SONG Y， et al. CT103A， a novel fully human BCMA-targeting CAR-T cells， in patients with relapsed/refractory multiple myeloma： Updated results of phase 1b/2 study （FUMANBA-1）［J］. J Clin Oncol， 2023， 41（）： 8025-8025. doi:10.1200/jco.2023.41.16_suppl.8025 doi: 10.1200/jco.2023.41.16_suppl.8025
19	FU C. Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma［J］.Blood， 2023， 142（）： 4845. doi:10.1182/blood-2023-184373 doi: 10.1182/blood-2023-184373
20	CHEN W， FU C， FANG B， et al. Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells （Zevorcabtagene Autoleucel） in Patients with Relapsed/Refractory Multiple Myeloma［J］. Blood， 2022， 140（）： 4564-4565. doi:10.1182/blood-2022-168610 doi: 10.1182/blood-2022-168610
21	WANG Z， ZHOU G， RISU N， et al. Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells［J］. Cell Transplantation， 2020， 29： 096368972092082. doi:10.1177/0963689720920825 doi: 10.1177/0963689720920825
22	GARFALL A L， COHEN A D， SUSANIBAR-ADANIYA S P， et al. Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy［J］. Blood Cancer Discov， 2023，4（2）：118-133. doi:10.1158/2643-3230.bcd-22-0074 doi: 10.1158/2643-3230.bcd-22-0074
23	SHI X， YAN L， SHANG J， et al. Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma［J］. Am J Hematol， 2022，97（5）：537-547. doi:10.1002/ajh.26486 doi: 10.1002/ajh.26486
24	ZHOU Z， LIU X， ZHANG X， et al. Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma［J］.Transplant Cell Ther， 2024，30（11）：1080.e1-1080.e11. doi:10.1016/j.jtct.2024.08.024 doi: 10.1016/j.jtct.2024.08.024
25	LI C. Phase I Clinical Study of a Fully Human BCMA-targeting CAR （CT103A） Combined With Selinexor in the Treatment of Patients With Relapsed/Refractory Extramedullary Multiple Myeloma： NCT05201118［R］. clinicaltrials.gov， 2022. doi:10.1182/blood-2023-181394 doi: 10.1182/blood-2023-181394
26	MOHAN M. A Multicenter Phase Ⅱ Study of Maintenance Belantamab Mafodotin （Blenrep^®） After BCMA-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma： NCT05117008［R］. clinicaltrials.gov， 2023.
27	FU B， LIU R， GAO G， et al. Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy［J］. Front Immunol， 2024，15：1433774. doi:10.3389/fimmu.2024.1433774 doi: 10.3389/fimmu.2024.1433774
28	LI W， ZHANG B， CAO W， et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing［J］. Exp Hematol Oncol， 2023，12（1）：44. doi:10.1186/s40164-023-00402-5 doi: 10.1186/s40164-023-00402-5
29	LEDERGOR G， FAN Z， WU K， et al. CD4⁺ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy［J］. Blood Adv， 2024，8（13）：3562-3575. doi:10.1182/bloodadvances.2023012416 doi: 10.1182/bloodadvances.2023012416
30	LEE H， AHN S， MAITY R， et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma［J］. Nat Med， 2023，29（9）：2295-2306. doi:10.1038/s41591-023-02491-5 doi: 10.1038/s41591-023-02491-5
31	SAMUR M K， FULCINITI M， AKTAS SAMUR A， et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma［J］. Nat Commun，2021，12（1）：868. doi:10.1038/s41467-021-21177-5 doi: 10.1038/s41467-021-21177-5
32	FU B， LIU R， GAO G， et al. Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy［J］. Front Immunol， 2024，15：1433774. doi:10.3389/fimmu.2024.1433774 doi: 10.3389/fimmu.2024.1433774
33	VAN OEKELEN O， NATH K， MOUHIEDDINE T H， et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy［J］. Blood， 2023，141（7）：756-765. doi:10.1182/blood.2022017848 doi: 10.1182/blood.2022017848
34	CHEN D， WANG X， CHEN Z， et al. Subsequent anti‐myeloma therapy after maturation antigen （ BCMA ） chimeric antigen receptor （ CAR ）‐T cell （ HDS269B ） treatment in patients with relapsed/refractory multiple myeloma［J］. Am J Hematol， 2022，97（12）：E478-E481. doi:10.1002/ajh.26745 doi: 10.1002/ajh.26745
35	CHARI A， MINNEMA M C， BERDEJA J G， et al. Talquetamab， a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma［J］. N Engl J Med， 2022，387（24）：2232-2244. doi:10.1056/nejmoa2204591 doi: 10.1056/nejmoa2204591
36	TRUDEL S， COHEN A D， KRISHNAN A Y， et al. Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma （RRMM）： Updated Results from an Ongoing Phase I Study［J］. Blood， 2021，138 （）： 157. doi:10.1182/blood-2021-147983 doi: 10.1182/blood-2021-147983
37	TOUZEAU C， KRISHNAN A Y， MOREAU P， et al. Efficacy and safety of teclistamab （tec）， a B-cell maturation antigen （BCMA） x CD3 bispecific antibody， in patients （pts） with relapsed/refractory multiple myeloma （RRMM） after exposure to other BCMA-targeted agents［J］. J Clin Oncol， 2022， 40（）： 8013. doi:10.1200/jco.2022.40.16_suppl.8013 doi: 10.1200/jco.2022.40.16_suppl.8013
38	VAN OEKELEN O， MOUHIEDDINE T H， PAN D， et al. Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T［J］. Blood， 2021， 138（）： 2704. doi:10.1182/blood-2021-152243 doi: 10.1182/blood-2021-152243
39	CHARI A， VOGL D T， JAGANNATH S， et al. Selinexor‐based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy［J］. Br J Haematol， 2020，189（4）：e126-e130. doi:10.1111/bjh.16550 doi: 10.1111/bjh.16550
40	HUANG H. Clinical Trial for the Safety and Efficacy of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy： NCT04541368［R］. clinicaltrials.gov， 2020. doi:10.31525/ct1-nct04272151 doi: 10.31525/ct1-nct04272151
41	CHUNG A. Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After or Refractory to Anti-BCMA CAR-T Therapies： NCT05191472［R］. clinicaltrials.gov， 2022. doi:10.1182/blood-2022-170744 doi: 10.1182/blood-2022-170744
42	MAILANKODY S， DEVLIN S M， LANDA J， et al. GPRC5D-Targeted CAR T Cells for Myeloma［J］. N Engl J Med， 2022，387（13）：1196-1206. doi:10.1056/nejmc2213985 doi: 10.1056/nejmc2213985
43	XIA J， LI H， YAN Z， et al. Anti-G Protein-Coupled Receptor， Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma： A Single-Arm， Phase Ⅱ Trial［J］. J Clin Oncol， 2023，41（14）：2583-2593. doi:10.1200/jco.22.01824 doi: 10.1200/jco.22.01824
44	石亚群，俞妍慧. 嵌合抗原受体T细胞治疗致细胞因子释放综合征与神经毒性的现状及展望［J］. 实用医学杂志，2021，37（2）：268-271.

CAR-T产品	胞外结构	总体反应率/%	完全反应率/%	细胞因子释放综合征发生率/%	免疫效应细胞相关神经毒性综合征发生率/%
ide-cel	鼠源单链可变区抗体片段	73	33	84	18
cilta-cel	双特异性驼可变区抗体片段	97.9	82.5	95	21
eque-cel	人源单链可变区抗体片段	96	74.3	94.4	1.2
zevor-cel	人源单链可变区抗体片段	92.8	42.4	90.2	2.0

[1]	Chunfang KONG,Anna LI,Bo KE,Weirong DING,Tingting LIU,Huan FU,Tingting ZHANG,Chenghao JIN,Mei. WU. The inhibitory effect and molecular mechanism of 6-gingerol on human multiple myeloma cells [J]. The Journal of Practical Medicine, 2024, 40(23): 3291-3297.
[2]	Sishi XU,Peipei. YE. Clinical research progress of BTK inhibitors in the treatment of mantle cell lymphoma [J]. The Journal of Practical Medicine, 2024, 40(17): 2363-2368.
[3]	ZHANG Ying, FU Xian, ZENG Xianfan, XU Jie, LIU Hongying, LI Xianliang, GAO Qingchun.. Correlation between internal carotid artery wall shear stress and relapse in acute ischemic cerebrovascular disease [J]. The Journal of Practical Medicine, 2023, 39(6): 738-741.
[4]	ZHANG Ling, JIN Chenghao, KONG Chun⁃ fang. . Mechanism of glucocorticoid resistance in multiple myeloma [J]. The Journal of Practical Medicine, 2023, 39(11): 1457-1460.
[5]	LIU Xiaoli, ZHOU Lin, HAN Chongxu. Extracellular vesicle，a new marker for diagnosis and prognosis of myeloma [J]. The Journal of Practical Medicine, 2021, 37(8): 1084-1092.
[6]	LI Zhichao, GUO Xia, WANG Shi, YIN Wei.. Effects of Huaiqihuang Granule on immune function in children with recurrent systemic lupus erythemato⁃sus [J]. The Journal of Practical Medicine, 2021, 37(4): 525-529.
[7]	QU Jing, XIAO Bin, LI Linhai, ZENG Tao.. An analysis on laboratory characteristics of multiple myeloma complicated with renal injury [J]. The Journal of Practical Medicine, 2021, 37(15): 2003-2011.

Advances in BCMA⁃CAR⁃T therapy of multiple myeloma and management after relapse

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 44

Related Articles 7

Recommended Articles

Metrics

Comments